These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 34167853)

  • 61. Induction of protective immunity against brucellosis in mice by vaccination with a combination of naloxone, alum, and heat-killed Brucella melitensis 16 M.
    Motaharinia Y; Rezaee MA; Rashidi A; Jalili A; Rezaie MJ; Shapouri R; Hossieni W; Rahmani MR
    J Microbiol Immunol Infect; 2013 Aug; 46(4):253-8. PubMed ID: 22727892
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Simultaneous immunization of mice with Omp31 and TF provides protection against Brucella melitensis infection.
    Ghasemi A; Jeddi-Tehrani M; Mautner J; Salari MH; Zarnani AH
    Vaccine; 2015 Oct; 33(42):5532-5538. PubMed ID: 26384448
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Humoral immunity and CD4+ Th1 cells are both necessary for a fully protective immune response upon secondary infection with Brucella melitensis.
    Vitry MA; Hanot Mambres D; De Trez C; Akira S; Ryffel B; Letesson JJ; Muraille E
    J Immunol; 2014 Apr; 192(8):3740-52. PubMed ID: 24646742
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparison of the efficacy of Brucella abortus strain RB51 and Brucella melitensis Rev. 1 live vaccines against experimental infection with Brucella melitensis in pregnant ewes.
    el Idrissi AH; Benkirane A; el Maadoudi M; Bouslikhane M; Berrada J; Zerouali A
    Rev Sci Tech; 2001 Dec; 20(3):741-7. PubMed ID: 11732416
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy evaluation of live Escherichia coli expression Brucella P39 protein combined with CpG oligodeoxynucleotides vaccine against Brucella melitensis 16M, in BALB/c mice.
    Al-Mariri A; Mahmoud NH; Hammoud R
    Biologicals; 2012 Mar; 40(2):140-5. PubMed ID: 22296786
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Protective efficacy and safety of Brucella melitensis 16MΔmucR against intraperitoneal and aerosol challenge in BALB/c mice.
    Arenas-Gamboa AM; Rice-Ficht AC; Kahl-McDonagh MM; Ficht TA
    Infect Immun; 2011 Sep; 79(9):3653-8. PubMed ID: 21708998
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Vaccine Candidate Brucella melitensis 16M
    Hensel ME; Garcia-Gonzalez DG; Chaki SP; Hartwig A; Gordy PW; Bowen R; Ficht TA; Arenas-Gamboa AM
    mSphere; 2020 May; 5(3):. PubMed ID: 32404509
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cell mediated immune response after challenge in Omp25 liposome immunized mice contributes to protection against virulent Brucella abortus 544.
    Goel D; Rajendran V; Ghosh PC; Bhatnagar R
    Vaccine; 2013 Feb; 31(8):1231-7. PubMed ID: 23273966
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Vaccination with recombinant L7/L12-truncated Omp31 protein induces protection against Brucella infection in BALB/c mice.
    Golshani M; Rafati S; Dashti A; Gholami E; Siadat SD; Oloomi M; Jafari A; Bouzari S
    Mol Immunol; 2015 Jun; 65(2):287-92. PubMed ID: 25723468
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunological responses and protective efficacy against Brucella melitensis induced by bp26 and omp31 B. melitensis Rev.1 deletion mutants in sheep.
    Jacques I; Verger JM; Laroucau K; Grayon M; Vizcaino N; Peix A; Cortade F; Carreras F; Guilloteau LA
    Vaccine; 2007 Jan; 25(5):794-805. PubMed ID: 17070627
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immunoproteomic analysis of Brucella melitensis and identification of a new immunogenic candidate protein for the development of brucellosis subunit vaccine.
    Yang Y; Wang L; Yin J; Wang X; Cheng S; Lang X; Wang X; Qu H; Sun C; Wang J; Zhang R
    Mol Immunol; 2011 Oct; 49(1-2):175-84. PubMed ID: 21943783
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Subcutaneous immunization with a novel immunogenic candidate (urease) confers protection against Brucella abortus and Brucella melitensis infections.
    Abkar M; Amani J; Sahebghadam Lotfi A; Nikbakht Brujeni G; Alamian S; Kamali M
    APMIS; 2015 Aug; 123(8):667-75. PubMed ID: 25939375
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Protective effect of a DNA vaccine containing an open reading frame with homology to an ABC-type transporter present in the genomic island 3 of Brucella abortus in BALB/c mice.
    Riquelme-Neira R; Retamal-Díaz A; Acuña F; Riquelme P; Rivera A; Sáez D; Oñate A
    Vaccine; 2013 Aug; 31(36):3663-7. PubMed ID: 23834811
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Protective Potential of Conjugated P. aeruginosa LPS -PLGA Nanoparticles in Mice as a Nanovaccine.
    Safari Zanjani L; Shapoury R; Dezfulian M; Mahdavi M; Shafieeardestani M
    Iran J Immunol; 2020 Mar; 17(1):75-86. PubMed ID: 32224543
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluation of novel Brucella melitensis unmarked deletion mutants for safety and efficacy in the goat model of brucellosis.
    Kahl-McDonagh MM; Elzer PH; Hagius SD; Walker JV; Perry QL; Seabury CM; den Hartigh AB; Tsolis RM; Adams LG; Davis DS; Ficht TA
    Vaccine; 2006 Jun; 24(24):5169-77. PubMed ID: 16697090
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evaluation of immunogenicity and protective activity in BALB/c mice of the 25-kDa major outer-membrane protein of Brucella melitensis (Omp25) expressed in Escherichia coli.
    Bowden RA; Cloeckaert A; Zygmunt MS; Dubray G
    J Med Microbiol; 1998 Jan; 47(1):39-48. PubMed ID: 9449948
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Brucellosis: Improved Diagnostics and Vaccine Insights from Synthetic Glycans.
    Bundle DR; McGiven J
    Acc Chem Res; 2017 Dec; 50(12):2958-2967. PubMed ID: 29219305
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination.
    Cassataro J; Pasquevich KA; Estein SM; Laplagne DA; Velikovsky CA; de la Barrera S; Bowden R; Fossati CA; Giambartolomei GH; Goldbaum FA
    Vaccine; 2007 May; 25(22):4437-46. PubMed ID: 17442465
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Nondividing but metabolically active gamma-irradiated Brucella melitensis is protective against virulent B. melitensis challenge in mice.
    Magnani DM; Harms JS; Durward MA; Splitter GA
    Infect Immun; 2009 Nov; 77(11):5181-9. PubMed ID: 19703982
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Novel Vaccine Candidates against Brucella melitensis Identified through Reverse Vaccinology Approach.
    Vishnu US; Sankarasubramanian J; Gunasekaran P; Rajendhran J
    OMICS; 2015 Nov; 19(11):722-9. PubMed ID: 26479901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.